Latest news - Novo Nordisk
Dec 15, 2024 · We plan to invest 2.9 billion Danish kroner to establish a cutting-edge quality control laboratory in Hillerød, Denmark. Environmental challenges have never been more critical or more urgent than they are today. But at Novo Nordisk, we never allow complexity to become a barrier to change.
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and …
Dec 20, 2024 · Bad news for Novo Nordisk (NVO-1.51%) Friday was good news for Eli Lilly (LLY-0.08%) and Viking Therapeutics (VKTX 0.07%), its two main rivals in the field of weight loss drugs.This morning, Novo ...
Novo Nordisk’s next-generation weight-loss drug CagriSema
6 days ago · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...
Novo Nordisk A/S: CagriSema demonstrates superior weight
6 days ago · Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and ...
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
6 days ago · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Novo Nordisk shares tumble as data on weight-loss drug trial …
6 days ago · Novo Nordisk and Eli Lilly are competing for dominance in a market that grew sevenfold in just three years to $24bn in 2023, according to data analytics firm Iqvia.
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
Nov 6, 2024 · Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief...
Company announcements & press releases - Novo Nordisk
Press releases are intended for the media. Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.
News Details - novonordisk.com
Oct 21, 2024 · Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial.
Novo Nordisk stock sees biggest loss in more than 20 years on …
6 days ago · Novo Nordisk stock sinks on news of its newest GLP-1 candidate. ... Novo Nordisk reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, ...